Moise J, Butler K, Payne J, Wampler R, Smith W, Fujimoto L, Golding L, Kiraly R, Harasaki H, Nose Y
Trans Am Soc Artif Intern Organs. 1985;31:202-5.
The LVAS utilizing an intrathoracic blood pump and a parathoracic, electrohydraulic energy converter has a number of promising features. These include: transcutaneous energy transmission and an implanted variable volume device which eliminate the need for percutaneous access; utilization of an intrathoracic blood pump and variable volume device which allow the diaphragm and abdominal cavity to remain intact; parathoracic or subcutaneous location of the transformer secondary, energy converter, internal battery and interconnecting elements allowing replacement with a minor surgical procedure; employment of the "biolized" continuous blood contacting surface which has the potential of long-term use without anticoagulants and utilization of an electrohydraulic energy converter which provides synchronization without requiring transducers and associated electronics and which provides lubrication of mechanical components. The development effort, which began separately in 1977 and has been conducted jointly by Nimbus and the Cleveland Clinic since 1980, has demonstrated that the above features can be incorporated in a reliable LVAS. In particular, the system in vivo test series have demonstrated the soundness of the basic concepts and led to refinements which were demonstrated in the 6-1/2 mo test. All elements of the system have been utilized during the in vivo test program. Component tests of significance include: LVAS and total heart blood pump in vivo experiments of up to 7 mos duration which demonstrate the blood compatibility of the biolized surface without the use of long-term anticoagulation.(ABSTRACT TRUNCATED AT 250 WORDS)
利用胸内血泵和胸旁电液压能量转换器的左心室辅助系统(LVAS)具有许多有前景的特性。这些特性包括:经皮能量传输以及植入的可变容积装置,这消除了经皮接入的需求;使用胸内血泵和可变容积装置,使膈肌和腹腔保持完整;变压器次级、能量转换器、内部电池和互连元件位于胸旁或皮下,允许通过小手术进行更换;采用“生物化”的连续血液接触表面,有可能在不使用抗凝剂的情况下长期使用,以及使用电液压能量转换器,该转换器无需传感器和相关电子设备即可实现同步,并为机械部件提供润滑。这项研发工作于1977年分别启动,自1980年以来由Nimbus公司和克利夫兰诊所联合开展,已证明上述特性可纳入可靠的左心室辅助系统。特别是,体内测试系列证明了基本概念的合理性,并促成了改进,这些改进在为期6个半月的测试中得到了体现。在体内测试项目中使用了该系统的所有元件。重要的部件测试包括:长达7个月的左心室辅助系统和全心脏血泵体内实验,该实验证明了生物化表面在不使用长期抗凝剂的情况下的血液相容性。(摘要截选至250字)